Physician profile
Khalaf Eid Rabadi
NPI 1285805937
$5,118.17
in general payments reported to CMS, 2019-2025
38 companies · $917 in 2025
The $917 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $303 · 2021: $85.48 · 2022: $592 · 2023: $348 · 2024: $1,421 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $757.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $545.06 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $393.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.81 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $387.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $283.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $262.07 | 2019-2022 | |
| Amgen INC. | $194.07 | 2019-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $181.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.60 | 2022-2025 | |
| Exact Sciences Corporation | $146.42 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $142.97 | 2022-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $138.08 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.01 | 2019-2024 | Xifaxan |
| Abbvie INC. | $100.84 | 2019-2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalaf Rabadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.